Skip to main content
. 2018 Jun 12;5:2054358118778573. doi: 10.1177/2054358118778573

Table 1.

Structure, Stability, Estimated Number of Global Injections, Number of Confounded and Unconfounded Reports of NSF, Classification by the European Medicines Agency, US Food and Drug Administration (FDA) and American College of Radiology, and Health Canada Guidelines for Patients With Severe Chronic Kidney Disease and Acute Kidney Injury Among Currently Approved Gadolinium-Based Contrast Agents for Clinical Use in Canada.

Agent Structure Stability (log Keq) Estimated number of global administrations (millions) Number of unconfounded cases of NSF Number of confounded cases of NSF EMA Classification FDA and ACR Classification Health Canada position
Gadodiamide (Omniscan, GE Healthcare) Linear nonionic 16.9 47 438 90 High risk I Absolutely contraindicated
Gadopentetate dimeglumine (Magnevist, Bayer Pharmaceuticals) Linear ionic 22.5 95 135 276 High risk I Absolutely contraindicated
Gadoversetamide (Optimark, Guerbet Group) Linear nonionic 16.6 0.8 7 11 High risk I Absolutely contraindicated
Gadobenate dimeglumine (MultiHance, Bracco Pharmaceuticals) Linear ionic 22.6 30 0 32 Medium risk II May be used with extreme caution
Gadoxetate disodium (Primovist, Bayer Pharmaceuticals) Linear nonionic 23.5 4.3 0 0 Medium risk III May be used with extreme caution
Gadoteridol (Prohance, Bracco Pharmaceuticals) Macrocyclic nonionic 23.8 22 1 or 2 37 Low Risk II May be used with extreme caution
Gadoterate meglumine (Dotarem, Guerbet Group) Macrocyclic ionic 25.8 65 0 or 1 7 Low risk II NAa
Gadobutrol (Gadovist, Bayer Pharmaceuticals) Macrocyclic nonionic 21.8 5.7 3 8 Low risk II May be used with extreme caution

Note. NSF = nephrogenic systemic fibrosis; EMA = European Medicines Agency; FDA = Food and Drug Administration; ACR = American College of Radiology.

a

Gadoteric acid was not available for clinical use in Canada at time of most recent Health Canada update on NSF.9